Stocks of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) traded higher last session on Wall Street, down -1.45% to $10.17.
RXRX stock price is now -8.49% away from the 50-day moving average and 9.14% away from the 200-day moving average. The market capitalization of the company currently stands at $2.19B.
With the price target of $8, Morgan Stanley recently initiated with Equal-Weight rating for Recursion Pharmaceuticals Inc (NASDAQ: RXRX). On March 16, 2023, Needham recently initiated its ‘Buy’ rating on the stock quoting a target price of $17, while ‘KeyBanc Capital Markets’ rates the stock as ‘Overweight’
In other news, Marriott Tina, President and COO sold 8,000 shares of the company’s stock on Mar 21 ’24. The stock was sold for $85,980 at an average price of $10.75. Upon completion of the transaction, the President and COO now directly owns 639,982 shares in the company, valued at $6.51 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 19 ’24, Director Borgeson Blake sold 20,054 shares of the business’s stock. A total of $216,423 was realized by selling the stock at an average price of $10.79. This leaves the insider owning 7,252,755 shares of the company worth $73.76 million. A total of 32.11% of the company’s stock is owned by insiders.
During the past 12 months, Recursion Pharmaceuticals Inc has had a low of $4.54 and a high of $16.75. As of last week, the company has a debt-to-equity ratio of 0.11, a current ratio of 4.70, and a quick ratio of 4.70. The fifty day moving average price for RXRX is $11.10 and a two-hundred day moving average price translates $9.32 for the stock.
The latest earnings results from Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$0.42, beating analysts’ expectations of -$0.45 by 0.03. This compares to -$0.31 EPS in the same period last year. The net profit margin was -735.99% and return on equity was -69.12% for RXRX. The company reported revenue of $10.89 million for the quarter, compared to $13.68 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -20.36 percent. For the current quarter, analysts expect RXRX to generate $12.65M in revenue.
